News | November 16, 2010

New Study Shows PEM Scanners May Reduce Unnecessary Breast Biopsies

November 15, 2010 — The Radiology journal released new data from an National Institutes of Health (NIH)-sponsored, multisite study of hundreds of women with newly diagnosed breast cancer that shows positron emission mammography (PEM) may reduce unnecessary breast biopsies. The study found PEM was significantly more precise at identifying benign and cancerous lesions, in what scientists call "positive predictive value" or "PPV," therefore reducing the number of unnecessary biopsies.  

A common physician complaint regarding the use of breast magnetic resonance imaging (MRI) is its tendency to identify suspicious lesions, requiring biopsies which ultimately are found to be benign. This finding is a welcome outcome for women and physicians looking for ways to reduce the patient trauma associated with biopsies and for payors looking to reduce the costs associated with unnecessary procedures.

The 388-woman study showed that PEM not only demonstrated a six percent improvement in specificity at comparably high sensitivity, but also that PEM had 31 fewer unnecessary biopsies and 26 percent higher PPV than breast MRI. These results are also particularly significant for those women who cannot tolerate an MR exam and require an alternate imaging tool.

"The results of this study mean that not only do physicians have an additional, powerful tool to help treat breast cancer, but also that PEM is a legitimate and better alternative for the 16 percent of women who cannot tolerate MR due to claustrophobia, metallic implants, body habitus or gadolinium reaction," said Wendie Berg, M.D., Ph.D. and principal investigator for the trial.

PEM scanners are high-resolution breast positron emission tomography (PET) systems that can show the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment. Other imaging systems, such as mammography and ultrasound, show only the location, not the metabolic phase.

The NIH-sponsored multisite study (NIH grant 5R44CA103102) examined women with newly-diagnosed breast cancer. Patients were accrued from six leading clinical centers across the country: ARS Johns Hopkins Green Spring, Boca Raton Community Hospital, Scripps Clinic-Scripps Green Hospital, University of North Carolina, University of Southern California Norris Cancer Center and Anne Arundel Medical Center.

For more information: www.naviscan.com

Related Content

Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Breast Density Advocate Nancy M. Cappello Passes Away

Nancy Cappello. Image courtesy of AreYouDense.org.

News | Breast Density | November 15, 2018 | Jeff Zagoudis, Associate Editor
Imaging Technology News extends its condolences to the family, friends and colleagues of Nancy M. Cappello, Ph.D., who...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...